Dermatitis Atopic Clinical Trial
Official title:
A Multi-center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Primary Objective: - Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus. Secondary Objectives: - Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus. - To evaluate the efficacy of dupilumab in AD participants with chronic pruritus. - To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD.
AD participants: A 20-week Observation Period including 16 weeks of treatment for AD participants and a 4-week follow-up period; Healthy participants: 8 days observation period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06015308 -
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
|
Phase 2 | |
| Completed |
NCT04135560 -
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT06130566 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT06192563 -
A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
|
||
| Completed |
NCT05624112 -
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
|
Phase 4 | |
| Recruiting |
NCT06407934 -
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | |
| Active, not recruiting |
NCT03992417 -
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
|
||
| Recruiting |
NCT06224348 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
|
Phase 3 | |
| Completed |
NCT05214326 -
A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries
|
||
| Recruiting |
NCT06241118 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05983068 -
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT04718870 -
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT05235724 -
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
|
||
| Recruiting |
NCT06181435 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
|
Phase 3 | |
| Recruiting |
NCT05492578 -
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
|
Phase 2 | |
| Recruiting |
NCT03687359 -
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
|
||
| Active, not recruiting |
NCT03849716 -
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
|
||
| Recruiting |
NCT05769777 -
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
|
Phase 2 |